CSL Seqirus exists to transform protection against influenza
CSL Seqirus exists to transform protection against influenza. As the only vaccine company with a singular global focus on influenza, we work tirelessly on cutting-edge research, transformative technologies, and the latest methods of production and distribution. Together with our partners we're on the front line every day, protecting communities from seasonal influenza and global pandemic threats. Our portfolio of products offers the latest in influenza technology.
Flucelvax,first and only cell-based flu vaccine approved for patients 6+
Fluad, first and only adjuvanted flu vaccine for patients 65+
Afluria, traditional egg-based flu vaccine
Brands: Flucelvax,first and only cell-based flu vaccine approved for patients 6+
Fluad, first and only adjuvanted flu vaccine for patients 65+
Afluria, traditional egg-based flu vaccine